A domestic biotech company has expanded its strategic options beyond early-stage licensing of antibody-drug conjugate (ADC) therapies, opening the door to advancing candidates through late-stage clinical trials. LegoChem Biosciences secured funding from the National Growth Fund, giving it long-term capital to independently conduct Phase 2 and Phase 3 trials for its core pipelines.
According to financial authorities on the 26th, the Financial Services Commission approved direct equity investment in LegoChem Biosciences at a fund management committee meeting held on the 25th. It marks the National Growth Fund’s first direct investment in a listed company and its first direct investment in a biotech firm.
The investment consists of capital from the Advanced Strategic Industries Fund and from major shareholder Orion and domestic institutional investors. The fundraising structure includes convertible bonds and convertible preferred shares issued through a third-party allocation. The instruments have a 10-year maturity. The issuance price was determined under the Capital Markets Act formula, with no discount applied.
Measures were also put in place to reduce near-term overhang concerns. The convertible preferred shares are subject to a one-year lock-up, while the convertible bonds are restricted from partial transfers for one year. Conversion rights may be exercised only after 24 months from issuance.
Orion’s participation reflects the National Growth Fund’s private-sector matching structure. “This was not purely policy funding coming in, but a 1:1 matching structure with private capital, which is why Orion also participated,” a LegoChem Biosciences official said.
The key point is how the funds will be used. The company plans to allocate the capital to R&D and clinical development rather than mergers and acquisitions. Specifically, the goal is to independently advance key pipelines through Phase 2 and Phase 3 trials and develop next-generation ADC platforms.
LegoChem Biosciences is regarded as a leading success case in Korea’s biotech licensing sector. Since its founding in 2006, it has completed multiple technology transfer deals with global pharmaceutical companies starting with a breast cancer treatment in 2015, generating cumulative export performance in the multi-billion-dollar range.
ADCs are cancer therapies that combine antibodies targeting cancer cells with anti-cancer drugs. By minimizing damage to healthy cells while precisely targeting tumors, the modality is viewed by global pharmaceutical companies as a next-generation oncology platform. LegoChem Biosciences is currently conducting multiple global clinical trials, including a Phase 3 trial for a breast cancer therapy.
The company was selected as the first biotech investment target of the National Growth Fund due to its track record in technology transfers and global clinical experience. “We have steadily built global licensing achievements, clinical data, and a recognized track record in the ADC field,” a company official said. “We believe those factors were highly valued in our selection as the first case.”
The company, which already holds a substantial cash position, says the additional funding carries a different purpose. Existing cash is used for ongoing operations and pipeline management, while the new funding is intended as long-term investment capital aimed at global drug launches. As policy funds with limited voting rights, the investment is not expected to change governance, including control or board composition.
With this investment, LegoChem Biosciences has expanded its strategic flexibility. Korean biotechs often choose early- or mid-stage licensing due to the high cost burden of clinical trials. The new funding gives the company room to independently advance core pipelines further into stages where higher value can be realized.
However, late-stage development involves significantly higher costs and failure risk, and competition in the global ADC market is intensifying, making it an open question whether the funding will translate into successful clinical outcomes and follow-on licensing deals.
“Just because this funding has been secured does not mean our licensing strategy is changing,” a LegoChem Biosciences official said. “However, it does give us more flexibility to continue internal development alongside licensing.”
“Most biotechs are forced by circumstances to pursue early-stage licensing,” the official added. “Ultimately, however, progressing into Phase 2 and 3 trials allows for higher-value licensing opportunities. This investment gives us more strategic options.”